VRSA, VISA, and GISA: The dilemma behind the name game

Clinical Microbiology Newsletter

Volumn 22, Issue 7, 2000, Pages 49-53

  Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE; METICILLIN; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; HOSPITAL INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0034177808     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-4399(00)88583-9     Document Type: Short Survey

References (46)

1. Ogston, A. 1883. Micrococcus poisoning. J. Anat. Physiol. (London) 17:24-58.
2. Weinstein, M.P. et al. 1997. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin. Infect. Dis. 24:584-602.
3. Cockerill III, F.R. et al. 1997. Analysis of 281,797 consecutive blood cultures performed over an eight-year period: Trends in microorganisms isolated and the value of anaerobic culture of blood. Clin. Infect. Dis. 24:403-418.
4. Mortara, L.A. and A.S. Bayer. 1993. Staphylococcus aureus bacteremia and endocarditis. Infect. Dis. Clin. North Am. 7:53-68.
5. Struelens, M.J., R. Mertens, and the Groupement pour le Dépistage, l'Etude et la prévention des infections hospitalières. 1994. National survey of methicillin-resistant Staphylococcus aureus. Eur. J. Clin. Microbiol. Infect. Dis. 13:56-63.
6. Fekety, F.R., Jr. 1964. The epidemiology and prevention of staphylococcal infection. Medicine 43:593-618.
7. Lowy, F.D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339:520-532.
8. Armstrong, G.L., J. Hollingsworth, and J.G. Morris, Jr. 1998. Bacterial food-borne disease, p. 109-138. In A.S. Evan and P.S. Brachman (ed.) Bacterial Infections of Humans. Epidemiology and Control, 3rd Ed. Plenum Medical Book Company, New York.
9. Davis, J.P. et al. 1980. Toxic-shock syndrome. N. Engl. J. Med. 303:1429-1435.
10. Karchmer, A.W. 1992. Staphylococcal endocarditis. p. 225-249. In D. Kaye (ed.), Infective Endocarditis, 2nd Ed. Raven Press, Ltd., New York.
11. Waldvogel, F.A. and H. Vasey. 1980. Osteomyelitis: The past decade. N. Engl. J. Med. 303:360-363.
12. Simon, H.J., S.J. Yaffe, and L. Gluck. 1961. Effective control of staphylococci in a nursery. N. Engl. J. Med. 265:1171-1176.
13. National Nosocomial Infections Surveillance System. 1996. National nosocomial infections surveillance (NNIS) report, data summary from october 1986-april 1996, issued May 1996. Am. J. Infect. Control. 24:380-388.
14. Panlilio, A.L. et al. 1992. Methicillin-resistant Staphylococcus aureus in U.S. Hospitals, 1975-1991. Infect. Control Hosp. Epidemiol. 13:582-586.
15. Vallés, J., C. León, and F. Alvarez-Lerma. 1997. Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and prognosis. Clin. Infect. Dis. 24:387-395.
16. Kauffman, C.A. and S.F. Bradley. 1997. Epidemiology of community-acquired infection. p. 287-308. In K. B. Crossley, and G. L. Archer (ed.), The Staphylococci in Human Disease. Churchill Livingstone, New York.
17. Maranan, M.C. et al. 1997. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms, and clinical relevance. Infect. Dis. Clin. North Am. 11:813-849.
18. Cunha, B.A. 1995. Vancomycin. Med. Clinics North Am. 79:817-831.
19. Kernodle, D.S. and A.B. Kaiser. 1996. Postoperative infections and antimicrobial prophylaxis, p. 2742-2756. In G.L. Mandell, J.E. Bennett, and R. Dolin (ed). Principles and Practice of Infectious Diseases. 4th Ed. Churchill Livingstone, New York.
20. Hiramatsu, K. et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
21. Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR 46:765-766.
22. Smith, T. et al. 1999. Emergence of vancomycin resistance in Staphylococcus aureus: Epidemiology and clinical significance. N. Engl. J. Med. 340:493-501.
23. Rotun, S.S. et al. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. 5:147-149.
24. Ploy, M.C. et al. 1998. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351:1212.
25. Howe, R.A. et al. 1998. Vancomycin-resistant Staphylococcus aureus. Lancet 351:602.
26. Anonymous. 1999. Vancomycin resistant staphylococci in Hong Kong. Brit. Med. J. 341:250
27. Ariza, J. et al. 1999. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 353:1587-1588.
28. Hiramatsu, K. et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
29. National Committee for Clinical Laboratory Standards. 1997. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 4th Ed., vol. 17, No. 2. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
30. National Committee for Clinical Laboratory Standards. 1997. Performance Standards for Antimicrobial Disk Susceptibility Tests, 6th Edition, vol. 17, No. 1. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
31. Goldstein, F., C.-J. Soussy, and A. Thabaut. 1996. Report of the Comité de l'Antibiogramme de la Société Française de Microbiologie. Definition of the clinical antibacterial spectrum of activity. Clin. Microbiol. Infect. 2:S40-S49.
32. Working Party of the British Society for Antimicrobial Chemotherapy. 1988. Breakpoints in in-vitro antibiotic susceptibility testing. J. Antimicrob. Chemother. 21:701-710.
33. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Resistance Updates 1:135-150.
34. Tenover, F.C. et al. 1998. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. 36:1020-1027.
35. Fitch, L. and A.P. Johnson. 1998. Reduced susceptibility to teicoplanin in a methicillin- resistant strain of Staphylococcus aureus. J. Antimicrob. Chemother. 41:578.
36. Lye, W., S.O. Leong, and E.J.C. Lee. 1993. Methicillin-resistant Staphylococcus aureus nasal carriage and infections in CAPD. Kidney Int. 43:1357-1362.
37. Kluytmans, J., A. van Belkum, and H. Verbrugh. 1997. Nasal carriage of Staphylococcus aureus: Epidemiology, underlying mechanisms, and associated risks. Clin. Microbiol. Rev. 10:505-520.
38. Zimakoff, J. et al. 1996. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark. J. Hosp. Infect. 33:289-300.
39. Boyce, J. 1996. Preventing staphylococcal infections by eradicating nasal carriage of Staphylococcus aureus: Proceeding with caution. Infect. Control Hosp. Epidemiol. 17:775-779.
40. Barett, S.P., R.V. Mummery, and B. Chattopadhyay. 1998. Trying to control MRSA causes more problems than it solves. J. Hosp. Infect. 39:85-93.
41. Irish, D. et al. 1998. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J. Hosp. Infect. 39:19-26.
42. Centers for Disease Control and Prevention. 1997. Interim guideline for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR 46:626-628, 635-636.
43. Centers for Disease Control and Prevention. 1995. Recommendations for preventing the spread of vancomycin resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 44 (no. RR-12).
44. Mercier, R.-C., H.H. Houlihan, and M.J. Rybak. 1997. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob. Agents Chemother. 41:1307-1312.
45. Mulazimoglu, L., S.D. Drenning, and V.L. Yu. 1996. In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (Trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob. Agents Chemother. 40:2428-2430.
46. Noble, W.C., Z. Virani, R.G.A. Cree. 1992. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. 93:195-198.